Antoni F. Z. Wisniewski
Antoni F. Z. Wisniewski has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
Andreas Brueckner
Novartis, Basel, Switzerland
1 shared publicationAndrew Bate
Pfizer, Walton-on-the-Hill, Surrey, UK
1 shared publicationBharat Thakrar
F. Hoffmann-La Roche, Basel, Switzerland
1 shared publication- Cédric Bousquet
Laboratory of Medical Informatics and Knowledge Engineering in e-Health, Sorbonne University, Paris, France
1 shared publication - G. Niklas Norén
Uppsala Monitoring Centre, Uppsala, Sweden
1 shared publication Gianmario Candore
European Medicines Agency, London, UK
1 shared publication
Latest Publications
- Open Access
- 7 March 2016
- Published by Springer Nature in Drug Safety
- Vol. 39 (6) , 469-490
Good Signal Detection Practices: Evidence from IMI PROTECT
Over a period of 5 years, the Innovative Medicines Initiative PROTECT (Pharmacoepidemiological Research on Outcomes of Therapeutics by a European ConsorTium) project has addressed key research questions relevant to the science of safety signal detection. The results of studies conducted into quantitative signal detection in spontaneous reporting, clinical trial and electronic health records databases are summarised and 39 recommendations have been formulated, many based on comparative analyses across a range of databases (e.g. regulatory, pharmaceutical company). The recommendations point to pragmatic steps that those working in the pharmacovigilance community can take to improve signal detection practices, whether in a national or international agency or in a pharmaceutical company setting. PROTECT has also pointed to areas of potentially fruitful future research and some areas where further effort is likely to yield less.
- 7 March 2016
- Published by Springer Nature in Drug Safety
- Vol. 39 (6) , 469-490
Open AccessGood Signal Detection Practices: Evidence from IMI PROTECT
Over a period of 5 years, the Innovative Medicines Initiative PROTECT (Pharmacoepidemiological Research on Outcomes of Therapeutics by a European ConsorTium) project has addressed key research questions relevant to the science of safety signal detection. The results of studies conducted into quantitative signal detection in spontaneous reporting, clinical trial and electronic health records databases are summarised and 39 recommendations have been formulated, many based on comparative analyses across a range of databases (e.g. regulatory, pharmaceutical company). The recommendations point to pragmatic steps that those working in the pharmacovigilance community can take to improve signal detection practices, whether in a national or international agency or in a pharmaceutical company setting. PROTECT has also pointed to areas of potentially fruitful future research and some areas where further effort is likely to yield less.